

## Datasheet: LNK033APC BATCH NUMBER 153491

## Description:LYNX RAPID APC ANTIBODY CONJUGATION KITName:APC CONJUGATION KITFormat:KitProduct Type:Conjugation KitQuantity:1 CONJUGATION for 1mg antibody

## **Product Details**

Applications	This product has been reported to work in the following applications. This information is derived from testing within our laboratories, peer-reviewed publications or personal communications from the originators. Please refer to references indicated for further information. For general protocol recommendations, please visit <u>www.bio-rad-antibodies.com/protocols</u> .							
	Conjugation	Yes	No	Not Determined	Suggested Dilution			
	We recommend that for each conjugation the user determines the best antibody:conjugate ratio.							
Product Information	<b>LYNX Rapid APC Antibody Conjugation Kit</b> ® enables the rapid conjugation of a pre-prepared lyophilized mixture containing Allophycocyanin (APC) label to an antibody or protein. Activation of proprietary reagents within the antibody-label solution results in directional covalent bonding of APC to the antibody.							
	The LYNX Rapid Conjugation kit® can be used to label small quantities of antibody/protein at near neutral pH, allowing a high conjugation efficiency with 100% antibody recovery.							
Reagents In The Kit	1 Vial of 1mg LYNX lyophilized APC mix							
	1 Vial LYNX Modifier rea	igent						
	1 Vial LYNX Quencher re	eagent						
Preparing The Antibody	The following buffer solu	tions are i	recommer	nded for preparing the	antibody:			
	10-50mM amine-free buffer (e.g HEPES, MES, MOPS and phosphate) pH range 6.5-8.5, although moderate concentrations of Tris buffer (<20mM) may be tolerated.							
	If possible, avoid buffers containing nucleophilic components such as primary amines and thiols (e.g. thiomersal/thimerosal) since they may react with LYNX							

chemicals. Azide (0.02-0.1%), EDTA, up to 50% Glycerol and common non-buffering salts and sugars have little or no effect on conjugation efficiency. For optimal results the antibody should be at a concentration of 1mg/ml, with a maximum volume of 1ml and a maximum antibody amount of 1mg. Antibody at a concentration of greater than 1mg/ml requires dilution. Antibody below 1mg/ml can still be used as long as the maximum volume is not exceeded. Using less than the recommended amount of antibody may result in unbound label, but this will be removed during subsequent application wash steps. Antibody below 0.5mg/ml should be concentrated before use with the kit. Instructions For Use 1. To the antibody sample add 1ul of the Modifier reagent for every 10ul of antibody and mix gently. 2. Pipette the mixed antibody-modifier sample directly onto the LYNX lyophilized mix and gently pipette up and down twice to resuspend. 3. Replace cap onto vial and incubate in the dark at room temperature (20-25°C) for 3 hours, or overnight if preferred. 4. After incubation, add 1ul of Quencher reagent for every 10ul of antibody used. Leave to stand for 30 minutes before use. References 1. Wang, Y. et al. (2010) Local host response to chlamydial urethral infection in male guinea pigs. Infect Immun.78: 1670-81. 2. Lacy, H.M. et al. (2011) Essential Role for Neutrophils in Pathogenesis and Adaptive Immunity in Chlamydia caviae Ocular Infections. Infect Immun. 79: 1889-97 3. Paget, C. et al. (2012) Interleukin-22 is produced by invariant natural killer T lymphocytes during influenza A virus infection: potential role in protection against lung epithelial damage. J Biol Chem. 287: 8816-29. 4. Seliger, C. et al. (2011) A rapid high-precision flow cytometry based technique for total white blood cell counting in chickens. Vet Immunol Immunopathol. 145: 86-99. 5. Fu, Y. et al. (2014) Development of a FACS-based assay for evaluating antiviral potency of compound in dengue infected peripheral blood mononuclear cells. J Virol Methods. 196: 18-24. 6. TraxImayr, M.W. et al. (2014) Construction of pH-sensitive Her2-binding IgG1-Fc by directed evolution. Biotechnol J. 9: 1013-22. 7. Wielgosz, M.M. et al. (2015) Generation of a lentiviral vector producer cell clone for human Wiskott-Aldrich syndrome gene therapy. Mol Ther Methods Clin Dev. 2: 14063. 8. Hofer, C.C. et al. (2015) Infection of Mice with Influenza A/WSN/33 (H1N1) Virus Alters Alveolar Type II Cell Phenotype. Am J Physiol Lung Cell Mol Physiol. ajplung.00373.2014. 9. Poh, C.M. et al. (2014) Damage to the blood-brain barrier during experimental cerebral malaria results from synergistic effects of CD8+ T cells with different specificities. Infect Immun. 82: 4854-64. 10. Hasenhindl, C. et al. (2014) Creating stable stem regions for loop elongation in Fcabs - insights from combining yeast surface display, in silico loop reconstruction and molecular

		11. War cancer. 12. Sch	d, S.T. <i>et al.</i> (2 <u>BMC Cancer.</u> uh, C.M. <i>et al.</i>	<u>16 (1): 154.</u> (2016) Covalent binding	n and tissu of placenta	e levels of VAP-1 in colorectal al derived proteins to silk fibroin er Sci Mater Med. 27 (12): 188.		
Storage		Newly-c addition Storage This pro	of a preserva in frost-free fr duct should b			g term storage however, the		
Guarante	e	12 mont	hs from date	of despatch				
Health Ar Informatio	-	<u>https://w</u> Lyophili: Modifier	laterial Safety Datasheet documentation #10532 #10546 #10548 available at: <u>ttps://www.bio-rad-antibodies.com/SDS/LNK033APC</u> yophilized APC Mix (10532) lodifier Reagent (10546) guencher Reagent (10548)					
Licensed	Use	Kingdon purchas right (wi use the purchas data ma purchas at. Ende	n patent numb e of this produ thout the right product to ma er cannot sell de using this ing licenses for avour House,	per 2446088 and associat act conveys to the buyer for to resell repackage or fur ke conjugates for researce or otherwise transfer this product, or its component or diagnostic and other us Langford Business Park	ed internat the limited, rther sublic ch and dev product, o ts to a third ses may be , Langford	batent protected under United tional patent applications. The non exclusive non-transferable cense) under these patents to relopment purposes only. The or its components, or materials o d party. Further information on e obtained by contacting Bio-Rac Lane, Kidlington, Oxon. OX5 <u>antibodies@bio-rad.com</u>		
Regulatory		For research purposes only						
orth & South nerica To find a ba	Fax: +1 919 87 Email: antibody	8 3751 _sales_us@bio		Tel: +44 (0)1865 852 700 Fax: +44 (0)1865 852 739 Email: antibody_sales_uk@bio-r		Tel: +49 (0) 89 8090 95 21 Fax: +49 (0) 89 8090 95 50 Email: antibody_sales_de@bio-rad.com		

## Printed on 18 Jan 2024

© 2024 Bio-Rad Laboratories Inc | Legal | Imprint